<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769457</url>
  </required_header>
  <id_info>
    <org_study_id>CEN_G_CA_8</org_study_id>
    <nct_id>NCT00769457</nct_id>
  </id_info>
  <brief_title>OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network</brief_title>
  <acronym>OptiLink-HF</acronym>
  <official_title>OptiLink HF Study (Optimization of Heart Failure Management Using Medtronic OptiVol® Fluid Status Monitoring and Medtronic CareLink® Network)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from heart failure and a markedly reduced pumping capacity and sometimes&#xD;
      desynchronization of the lower chambers of the heart have a higher risk of suffering sudden&#xD;
      cardiac death.&#xD;
&#xD;
      These patients can be treated with an Implantable Cardiac Defibrillator that terminates&#xD;
      dangerously fast heartbeats and in case of asynchronous pumping of the heart can also&#xD;
      re-synchronize the lower chambers of the heart (ICD- or CRT-D-system). Patients that moreover&#xD;
      suffered from a worsening of their cardiac status (cardiac decompensation) and had to be&#xD;
      hospitalized for this reason have a higher risc to have following decompensations. New&#xD;
      technology, incorporated into modern Medtronic ICD- and CRT-D-Systems, that measures the&#xD;
      amount of water in the lungs is able to warn before such a dangerous worsening occurs. If&#xD;
      coupled with modern data transmitting technology (CareLink), automatic information in case of&#xD;
      a worsening of the cardiac status can be sent to caregivers, who in turn can react timely in&#xD;
      order to prevent a worsening an subsequent hospitalization.&#xD;
&#xD;
      The study examines to which extent this new technology prevents potentially adverse cardiac&#xD;
      situations and / or hospitalizations and has an influence of the duration of patient´s lives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to establish whether the use of event-triggered HF-disease&#xD;
      management through Medtronic's OptiVol® fluid status monitoring with an automatically&#xD;
      generated wireless CareAlert® notification of the clinician via the Medtronic CareLink®&#xD;
      Network can reduce cardiovascular related hospitalizations and the number of deaths in a&#xD;
      subject population with HF and ICD / CRT-D treatment as compared to standard clinical&#xD;
      assessment. As a measure for the reduction of hospitalizations and deaths the rate of all&#xD;
      cause deaths or cardiovascular related hospitalizations will be determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off</measure>
    <time_frame>18 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of HF-related hospitalization during follow-up, HF-related hospitalization, Sum of follow-up days minus days alive and out of the hospital, All cause mortality, Cardiovascular Mortality,</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1002</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Access Arm</intervention_name>
    <description>Active OptiVol-System with CareAlert via CareLink</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Medtronic CRT-D and ICD-VR / DR with OptiVol, Conexus-Telemetry, CareLink:</other_name>
    <other_name>Concerto , Consulta , Virtuoso , Secura , Protecta XT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects have a Medtronic Virtuoso™ ICD single- or dual-chamber or Concerto™ CRT-D or&#xD;
             subsequently market released Medtronic device providing at least the same&#xD;
             functionality) implanted, including device replacement. Subjects with CRT-D must&#xD;
             fulfill CRT-indication as described in the ESC guidelines for cardiac pacing and&#xD;
             cardiac resynchronization therapy 2007: EF ≤ 35% and NYHA III, and LVEDD ≥ 55 mm, and&#xD;
             QRS ≥ 120 ms, and optimized therapy&#xD;
&#xD;
          -  Subjects with stable chronic heart failure (CHF) in New York Heart Association (NYHA)&#xD;
             class II or III for at least 30 days and left ventricular ejection fraction of no more&#xD;
             than 35% (most recent measurement within 6 months prior to randomization by&#xD;
             echocardiography or contrast ventriculography, magnetic resonance or nuclear imaging,&#xD;
             based on local practice), on optimal target or maximal tolerated dose of&#xD;
             ACE-inhibitors or angiotensin receptor blockers, ß-blockers and diuretics if&#xD;
             clinically indicated to reduce fluid retention and one of the following criteria:&#xD;
&#xD;
          -  At least one hospitalization due to the heart failure within the last 12 months before&#xD;
             enrollment&#xD;
&#xD;
          -  Or one course of ambulatory IV-or oral diuretic treatment or a BNP value of &gt; 400&#xD;
             pg/ml or a NT-proBNP values &gt; 450 in subject &lt; 50 years, &gt; 900 (50-75 years) and &gt;&#xD;
             1800 subject of than 75 years old within 30 days of enrollment&#xD;
&#xD;
          -  Written informed consent by the subject for study participation prior to clinical&#xD;
             investigation plan specific procedures,&#xD;
&#xD;
          -  The subject must be able and willing to comply with the clinical investigation plan&#xD;
             and willing to remain available for follow-up visits to the study closure,&#xD;
&#xD;
          -  Subjects or the subject's caregiver must be willing and able to use the Medtronic&#xD;
             CareLink® monitor as instructed and to perform the required duties, if subject is&#xD;
             randomized to the access arm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic renal failure needing renal dialysis&#xD;
&#xD;
          -  Subjects with serum creatinine &gt; 2.5 mg/dl, measured within 14 days prior to&#xD;
             enrollment,&#xD;
&#xD;
          -  Subjects with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) as&#xD;
             determined by physician and documented in medical records (Stage III and Stage IV),&#xD;
&#xD;
          -  Subjects with suspected or confirmed COPD require a current test of lung function (not&#xD;
             more than 12 months before inclusion). If the &quot;forced expiratory volume&quot; is &lt;1.0&#xD;
             L/sec,the subject may not participate in the study,&#xD;
&#xD;
          -  Subjects on the heart transplantation list or subjects with transplanted hearts,&#xD;
&#xD;
          -  Subjects listed for valve replacement or interventional valve therapy,&#xD;
&#xD;
          -  Subjects with myocardial infarction within the last 40 days before implant. MI is&#xD;
             defined by typical changes in biochemical markers including troponin levels &gt; 3 times&#xD;
             the upper limits of normal and creatinine kinase &lt; 2 times of upper limit, or with&#xD;
             CKMB greater than the upper limit of normal, combined (for all enzymes) with at least&#xD;
             one of the following ischemic symptoms, ECG changes consistent of diagnostic ST-T wave&#xD;
             changes or pathologic Q waves or new LBBB,&#xD;
&#xD;
          -  Subjects with stroke within 40 days prior randomization,&#xD;
&#xD;
          -  Subjects who have had a percutaneous coronary intervention within 3 months prior to&#xD;
             randomization,&#xD;
&#xD;
          -  Subjects with cardiac surgery within 90 days of randomization,&#xD;
&#xD;
          -  Subjects with complex and uncorrected Congenital Heart Disease,&#xD;
&#xD;
          -  Subject's life expectancy is less than 18 months in the opinion of the physician,&#xD;
&#xD;
          -  Subjects in situations that would limit participation, not eligible to receive a&#xD;
             CareLink® monitor (e.g. hearing or speech impaired with no family member or caregiver&#xD;
             available to assist, or those who spend extended periods abroad, or those who intend&#xD;
             to enroll in a study that would preclude use of the monitor),&#xD;
&#xD;
          -  Subject is participating in a concurrent intervention study,&#xD;
&#xD;
          -  Subject or the subject's caregiver is unwilling to give consent for the release of&#xD;
             information for the evaluation or to give additional consent for the release of&#xD;
             subject medical and privacy data for CareLink® subjects,&#xD;
&#xD;
          -  Subjects with exclusion criteria required by local law (age &lt; 18, women who are&#xD;
             pregnant or breastfeeding)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boehm, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum des Saarlandes, Homburg-Saar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Brachmann, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Coburg GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg-Saar</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinikum-saarland.de/de/einrichtungen/kliniken_institute/kardiologie</url>
    <description>Klinik für Innere Medizin III - Kardiologie, Angiologie und internistische Intensivmedizin</description>
  </link>
  <reference>
    <citation>Brachmann J, Böhm M, Rybak K, Klein G, Butter C, Klemm H, Schomburg R, Siebermair J, Israel C, Sinha AM, Drexler H; OptiLink HF Study Executive Board and Investigators. Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink). Eur J Heart Fail. 2011 Jul;13(7):796-804. doi: 10.1093/eurjhf/hfr045. Epub 2011 May 8.</citation>
    <PMID>21555324</PMID>
  </reference>
  <results_reference>
    <citation>Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse B, Monteiro J, Israel C, Bimmel D, Käab S, Huegl B, Brachmann J; OptiLink HF Study Investigators. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J. 2016 Nov 1;37(41):3154-3163. Epub 2016 Mar 16.</citation>
    <PMID>26984864</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

